Larazotide: The Intestinal Gatekeeper
Your intestines have a selective barrier—imagine a bouncer at a club who decides what gets through. In celiac disease and other conditions, this barrier gets too permeable, like the bouncer falling asleep on the job. Larazotide is a synthetic peptide designed to keep that bouncer alert.
Here's what happens normally: your body produces a protein called zonulin that loosens your intestinal tight junctions when needed. But in celiac disease, gluten triggers excess zonulin release, which opens up gaps in your intestinal wall. This lets undigested food particles and bacteria slip through into your bloodstream, where your immune system attacks them, causing inflammation and symptoms.
Larazotide works by blocking zonulin's ability to do its job—it essentially clamps down on the receptor that zonulin uses to signal "open these junctions." By preventing that signal, larazotide keeps your intestinal barrier sealed tight, preventing those harmful particles from leaking through in the first place.
In clinical trials, people taking larazotide showed reduced intestinal permeability and fewer symptoms, even when exposed to gluten. It's a targeted fix addressing the actual mechanism that goes wrong, rather than just treating symptoms afterward. It's still being studied, but it represents a fundamentally different approach to managing intestinal barrier problems.
Dosage Information
Typical Dose
0.5-2 mg three times daily (Phase 2 trial doses)
Frequency
Three times daily before meals
Administration
Oral capsule
Half-Life
~2 hours
Notes
Phase 2 trials completed for celiac disease. Not yet FDA approved. Research use as a tight junction stabilizer for leaky gut applications. Oral bioavailability is intentionally limited — local gut action is the therapeutic target.
Why this matters
Oral peptide acting locally on intestinal tight junctions; minimal systemic absorption.
Where does Larazotide sit?
See how this peptide compares across all 150 peptides in our database.
Evidence Score
0.70
Compound Data
Molecular Formula
C32H55N9O10
Molecular Weight
725.80 g/mol
IUPAC Name
2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid
PubChem CID
9810532Potential Side Effects
Larazotide discussions
Quick Facts
- Administration
- Oral capsule
- Typical Dose
- 0.5-2 mg three times daily (Phase 2 trial doses)
- Frequency
- Three times daily before meals
- References
- 0 curated + 49 from PubMed
- Clinical Trials
- 28 registered
- Evidence Score
- 0.7 / 100
Frequently Asked Questions about Larazotide
What is Larazotide?
Larazotide acetate is a synthetic 8-amino-acid peptide derived from Zonula Occludens Toxin that acts as a tight junction regulator reducing intestinal permeability. It has completed Phase 2 clinical trials for celiac disease demonstrating significant reductions in intestinal permeability and symptoms. Larazotide is notable as a targeted pharmacological approach to intestinal barrier function — addressing the leaky gut mechanism that underlies multiple inflammatory and autoimmune conditions beyond celiac disease.
How does Larazotide work?
Larazotide acts as a competitive antagonist of zonulin — an endogenous protein that regulates tight junction permeability in the intestinal epithelium. Zonulin triggers the disassembly of tight junction proteins (claudins occludin ZO-1) increasing intestinal permeability and allowing luminal antigens to cross the epithelial barrier and trigger immune activation. By blocking the zonulin receptor on epithelial cells larazotide prevents tight junction disruption maintaining the intestinal barrier integrity. This mechanism is particularly relevant in celiac disease where gliadin triggers zonulin release causing the intestinal permeability that allows gluten peptides to trigger the immune response. Clinical trials have demonstrated reductions in intestinal permeability markers and symptom improvements even during gluten exposure.
What is the recommended dosage for Larazotide?
The typical dose is 0.5-2 mg three times daily (Phase 2 trial doses). Three times daily before meals. Administration: Oral capsule. Phase 2 trials completed for celiac disease. Not yet FDA approved. Research use as a tight junction stabilizer for leaky gut applications. Oral bioavailability is intentionally limited — local gut action is the therapeutic target.
What are the side effects of Larazotide?
Generally well tolerated in clinical trials. Headache (uncommon). Nausea (uncommon). Upper respiratory tract infection (uncommon in trials)
Questions reflect common community inquiries. This is not medical advice.